Christine Patch

Dr. Christine Patch


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2018 in BMJ
Verified
Journal Article
Closed access
PDF file
CTClare Turnbull
Clare Turnbull
RSRichard H Scott
Richard H Scott
ETEllen Thomas
Ellen Thomas
LJLouise Jones
Louise Jones
NMNirupa Murugaesu
Nirupa Murugaesu
MCMark J Caulfield
Mark J Caulfield
In partnership with NHS England, Genomics England’s ambitious plans to embed genomic medicine into routine patient care are well underway. Clare Turnbull and colleagues discuss its progress

7 March 2022 in Nature
Verified
Journal Article
Open access
PDF file
AKAthanasios Kousathanas
Athanasios Kousathanas
EPErola Pairo-Castineira
Erola Pairo-Castineira
KRKonrad Rawlik
Konrad Rawlik
ASAlex Stuckey
Alex Stuckey
COChristopher A. Odhams
Christopher A. Odhams
JBJ. Kenneth Baillie
J. Kenneth Baillie
Critical COVID-19 is caused by immune-mediated inflammatory lung injury. Host genetic variation influences the development of illness requiring critical care1 or hospitalization2–4 after infection with SARS-CoV-2. The GenOMICC (Genetics of Mortality in Critical Care) study enables the comparison of genomes from individuals who are critically ill with those of population controls to find underlying disease mechanisms. Here we use whole-genome sequencing in 7,491 critically ill individuals compared with 48,400 controls to discover and replicate 23 independent variants that significantly predispose to critical COVID-19. We identify 16 new independent associations, including variants within genes that are involved in interferon signalling (IL10RB and PLSCR1), leucocyte differentiation (BCL11A) and blood-type antigen secretor status (FUT2). Using transcriptome-wide association and colocalization to infer the effect of gene expression on disease severity, we find evidence that implicates multiple genes—including reduced expression of a membrane flippase (ATP11A), and increased expression of a mucin (MUC1)—in critical disease. Mendelian randomization provides evidence in support of causal roles for myeloid cell adhesion molecules (SELE, ICAM5 and CD209) and the coagulation factor F8, all of which are potentially druggable targets. Our results are broadly consistent with a multi-component model of COVID-19 pathophysiology, in which at least two distinct mechanisms can predispose to life-threatening disease: failure to control viral replication; or an enhanced tendency towards pulmonary inflammation and intravascular coagulation. We show that comparison between cases of critical illness and population controls is highly efficient for the detection of therapeutically relevant mechanisms of disease.

2 April 2018 in British Medical Bulletin
Verified
Journal Article
Open access
PDF file
CPChristine Patch
Christine Patch
AMAnna Middleton
Anna Middleton
Genomic technology can now deliver cost effective, targeted diagnosis and treatment for patients. Genetic counselling is a communication process empowering patients and families to make autonomous decisions and effectively use new genetic information. The skills of genetic counselling and expertise of genetic counsellors are integral to the effective implementation of genomic medicine. Original papers, reviews, guidelines, policy papers and web-resources. An international consensus on the definition of genetic counselling. Genetic counselling is necessary for implementation of genomic medicine. Models of genetic counselling. Genomic medicine is a growing and strategic priority for many health care systems. Genetic counselling is part of this. An evidence base is necessary, incorporating implementation and outcome research, to enable health care systems, practitioners, patients and families to maximize the utility (medically and psychologically) of the new genomic possibilities.

29 June 2010 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
EVEvangelos Vassos
Evangelos Vassos
DCDavid A. Collier
David A. Collier
SHSimon Holden
Simon Holden
CPChristine Patch
Christine Patch
DRDan Rujescu
Dan Rujescu
CLCathryn Lewis
Cathryn Lewis
The discovery of ‘high-risk’ de novo copy number variants (CNVs) associated with neuropsychiatric disorders such as schizophrenia offers the opportunity to translate these findings into useful tools for clinical geneticists. However, this will require estimation of penetrance for these variants, which has not yet been properly considered. To facilitate this process, we estimated the penetrance of CNVs associated with schizophrenia, at 15q13.3, 1q21.1, 15q11.2, 17p12, 2p16.3, 16p13.1 and 16p11.2 with a novel Bayesian method applied to pooled data from published case–control studies. For these CNVs, penetrance for schizophrenia was between 2 and 7.4%, which contrasts with the much higher penetrance for schizophrenia of the 22q11.2 deletions found in velo-cardio-facial syndrome. The highest penetrance was for 15q13.3 deletion (6–9% in individual studies) and the lowest was for 15q11.2 (2%). CNVs confer much higher risk for schizophrenia than common variants, but their penetrance is substantially lower than Mendelian disorders or other syndromic conditions. Since these CNVs predispose to multiple disorders, including epilepsy, autism and intellectual impairment, penetrance estimates will also need to take into account diagnostic specificity, and their overall penetrance for any neuropsychiatric disorder is likely to be much higher. Thus, although CNVs are still far from being clinically useful or relevant to genetic counselling for specific disorders, their detection may hold an important clinical value in predicting negative developmental outcomes.

24 June 2019 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
FFFlorence Fellmann
Florence Fellmann
CECarla G. van El
Carla G. van El
PCPhilippe Charron
Philippe Charron
KMKatarzyna Michaud
Katarzyna Michaud
HHHeidi C. Howard
Heidi C. Howard
Martina C CornelMartina C Cornel
Martina C Cornel
Sudden cardiac death (SCD) accounts for 10–20% of total mortality, i.e., one in five individuals will eventually die suddenly. Given the substantial genetic component of SCD in younger cases, postmortem genetic testing may be particularly useful in elucidating etiological factors in the cause of death in this subset. The identification of genes responsible for inherited cardiac diseases have led to the organization of cardiogenetic consultations in many countries worldwide. Expert recommendations are available, emphasizing the importance of genetic testing and appropriate information provision of affected individuals, as well as their relatives. However, the context of postmortem genetic testing raises some particular ethical, legal, and practical (including economic or financial) challenges. The Public and Professional Policy Committee of the European Society of Human Genetics (ESHG), together with international experts, developed recommendations on management of SCD after a workshop sponsored by the Brocher Foundation and ESHG in November 2016. These recommendations have been endorsed by the ESHG Board, the European Council of Legal Medicine, the European Society of Cardiology working group on myocardial and pericardial diseases, the ERN GUARD-HEART, and the Association for European Cardiovascular Pathology. They emphasize the importance of increasing the proportion of both medical and medicolegal autopsies and educating the professionals. Multidisciplinary collaboration is of utmost importance. Public funding should be allocated to reach these goals and allow public health evaluation.

1 September 2005 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
SSSimon Sanderson
Simon Sanderson
RZRon Zimmern
Ron Zimmern
MKMark Kroese
Mark Kroese
JHJulian Higgins
Julian Higgins
CPChristine Patch
Christine Patch
JEJon Emery
Jon Emery
Article Advances in genetic technology are increasing the availability of genetic tests, not only for rare single gene disorders, but also for common diseases such as breast and colo-rectal cancer. Before there can be widespread uptake of these tests, they must be evaluated to confirm the benefits of their use. But how should genetic tests be evaluated, given the speed at which new tests are emerging? One highly influential approach is the analytic validity, clinical validity, clinical utility and ethical, legal and social issues (ACCE) framework, which has provided a benchmark for the evaluation of genetic tests. The approach has been adopted and adapted by the United Kingdom Genetic Testing Network, with the help of the Public Health Genetics Unit in Cambridge, to evaluate new genetic tests for use in the National Health Service. We discuss a number of conceptual, methodological, and practical issues concerning the evaluation of genetic tests, based on lessons learned from applying the ACCE framework and from the UK experience, and make a number of recommendations to further strengthen the evaluation of genetic tests.